Key statistics
On Friday, Lineage Cell Therapeutics Inc (BT3:FRA) closed at 0.775, 12.32% above the 52 week low of 0.69 set on Nov 04, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 0.775 |
---|---|
High | 0.775 |
Low | 0.775 |
Bid | 0.825 |
Offer | 0.91 |
Previous close | 0.80 |
Average volume | 0.00 |
---|---|
Shares outstanding | 188.84m |
Free float | 188.00m |
P/E (TTM) | -- |
Market cap | 174.45m USD |
EPS (TTM) | -0.1342 USD |
Data delayed at least 15 minutes, as of Nov 08 2024 07:00 GMT.
More ▼
- Lineage Cell Therapeutics to Report Third Quarter 2024 Financial Results and Provide Business Update on November 14, 2024
- Lineage Cell Therapeutics to Present at the Maxim Group 2024 Virtual Healthcare Summit
- OpRegen® (RG6501) Phase 1/2a Results to Be Featured at International Society for Stem Cell Research (ISSCR) 2024 Copenhagen International Symposium
- Lineage Presents Preclinical Data on Its Auditory Neuronal Cell Transplant Program, ReSonance™, at the 59th Annual Inner Ear Biology Workshop
- Lineage Cell Therapeutics to Present at the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference
More ▼